Making computed tomography safer for patients with Crohn's disease. (1st February 2022)

• Record Type: Journal Article
• Authors: O'Grady, John; Carey, Brian W.; Kavanagh, Richard G.; O'Connell, Aislinn; O'Connor, Owen J.; Kenny-Walsh, Elizabeth; Zulquernain, Syed A.; Maher, Michael M.; Shanahan, Fergus
• Is Part Of: Scandinavian journal of gastroenterology. Volume 57:Number 2(2022)
• Page Start: 175
• Page End: 182
• Publication Date: 2022-02-01
• Subjects: Crohn's disease -- radiation safety -- computed tomography -- patient outcomes -- quality care; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2021.1994640
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background and aims: Computed tomography (CT), often more accessible than magnetic resonance imaging (MRI), remains widely used though radiation exposure is an obvious disadvantage. We previously showed that modern CT technology can achieve over 70% reduction in radiation-dose without loss of accuracy. Here, we compare low- versus conventional-dose CT in patients with known Crohn's disease to assess clinical confidence and accuracy of the low-dose procedure in the semi-acute setting. Methods: A comparative study of low-dose CT with full iterative reconstruction (IR) versus conventional-dose CT was conducted in 50 consecutive outpatients with Crohn's disease. Clinicians were provided with the low-dose images and reports, whereas conventional-dose images were reviewed after 4 weeks. Results: The clinical question was adequately addressed with low-dose IR imaging in all cases. Complications of Crohn's were detected in 37/50 (74%) with no disagreement between low- and conventional-dose imaging. The effective radiation dose reduction was 76.5% (low-dose mean 2.15 mSv versus conventional-dose CT 6.99 mSv). Conclusion: Low-dose IR CT is safe and accurate for evaluating distribution and complications of known Crohn's disease in the outpatient setting. We propose that low-dose radiation imaging should be adopted as standard-of-care for the evaluation of Crohn's disease and an acceptable alternative to MR particularly in the acute setting. ClinicalTrials.gov: NCT03140306.